Efficacy and safety of interferon-α in the treatment of corticodependent uveitis of paediatric Behçet's disease

Rheumatology

Volumn 46, Issue 10, 2007, Pages 1570-1573

  Guillaume Czitrom, Severine ^a   Berger, C ^b   Pajot, C ^c   Bodaghi, B ^d   Wechsler, B ^d   Kone Paut, I ^a  

^a BICÊTRE HOSPITAL   (France)

^b Saint Etienne Hospital   (France)

^c CHU PURPAN   (France)

^d PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

Author keywords

Beh et's disease in children; Interferon ; Treatment; Uveitis

Indexed keywords

ALPHA2A INTERFERON; COLCHICINE; CORTICOSTEROID; DISEASE MODIFYING ANTIRHEUMATIC DRUG; PARACETAMOL; PENICILLIN G; SALICYLIC ACID;

ARTICLE; BEHCET DISEASE; CATARACT; CLINICAL ARTICLE; DISEASE SEVERITY; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; FLU LIKE SYNDROME; HUMAN; LOW DRUG DOSE; MAJOR DEPRESSION; MALE; PRIORITY JOURNAL; RECURRENCE RISK; REMISSION; SCHOOL CHILD; UVEITIS; VEIN THROMBOSIS;

BEHCET SYNDROME; CHILD; DRUG ADMINISTRATION SCHEDULE; DRUG EVALUATION; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; GLUCOCORTICOIDS; HUMANS; INTERFERON ALFA-2A; MALE; PANUVEITIS; RECURRENCE; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 34848901715     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/kem199     Document Type: Article

References (28)

1. Evereklioglu C. Current concepts in the etiology and treatment of Behçet's disease. Surv Ophthalmol 2005;50:297-350.
2. Cochereau-Massin I, Wechsler B, Lehohang P et al. Pronostic oculaire de la maladie de Behçet. J Fr Ophtalmol 1992;15:343-7.
3. El Belhadji M, Hamdani M, Laouissi N, Zagloui K, Amraoui A, Benamour S. L'atteinte ophtalmologique de la maladie de Behçet. A propos de 520 cas. J Fr Ophtalmol 1997;20:592-8.
4. Tugal-Tutkun I, Onal S, Altan-Yaycioglu R, Altumbas HH, Urgancioglu M. Uveitis in Behçet's disease: An analysis of 880 patients. Am J Ophtalmol 2004;138:373-80.
5. Kone-Paut I, Yurdakul S, Bahrabri S et al. Clinical features of Behçet's disease in children: An international study of 86 cases. J Pediatr 1998;132:721-6.
6. Yazici H, Tuzun Y, Pazarli H et al. Influence of age of onset and patient's sex on the prevalence and severity of manifestations of Behçet's syndrome. Ann Rheum Dis 1984;43:788-9.
7. Zouboulis CC, Kotter I, Djawari D et al. Epidemiological features of Adamantiades Behçets disease in Germany and in Europe. Yonsei Med J 1997;38:411-22.
8. Matsuo T, Itami M, Nakagawa H, Nagayama M. The incidence and pathology of conjunctival ulceration in Behçet syndrome. Br J Ophtalmol 2002;86:140-3.
9. Tugal-Tutkun I, Urgancioglu M. Childhood-onset uveitis in Behcet disease: A descriptive study of 36 cases. Am J Ophthalmol 2003;136:1114-9.
10. Tugal-Tutkun I, Mundun A, Urgancioglu M et al. Efficacy of infliximab in the treatment of uveitis that is resistant to treatment with the combination of azathioprine, cyclosporine, and corticosteroids in Behcet's disease: An open-label trial. Arthritis Rheum 2005;52:2478-84.
11. Saurenmann RK, Levin AV, Rose JB et al. Tumour necrosis factor alpha inhibitors in the treatment of childhood uveitis. Rheumatology 2006;45:982-9.
12. Pipitone N, Olivieri I, Cantini F, Triolo G, Salvarani C. New approaches in the treatment of Adamantiades Behçet's disease. Curr Opin Rheumatol 2006;18:3-9.
13. Pirraglia MP, Priori R, Valesini G. Interferon α for ocular Behçets disease. Acta Ophtalmol Scand 1997;75:720-2.
14. Zouboulis CC, Orfanos CE. Treatment of Adamantiades-Behçets disesae with systemic interferon alpha. Arch Dermatol 1998;134:1010-6.
15. Alpsoy E, Durusoy C, Yilmaz E et al. Interferon alpha-2a in the treatment of Behçet's disease: A randomized placebo-controlled and double-blind study. Arch Dermatol 2002;138:467-71.
16. Wechsler B, Bodaghi B, LêThi Huong D et al. Efficacy of interferon alfa-2a in severe and refractory uveitis associated with Behçet's disease. Ocul Immunol Inflamm 2000;8:293-301.
17. Kötter I, Zierhut M, Ecksyein K et al. Human recombinant interferon alpha2a for the treatment of Behçet's disease with sight threatening posterior or panuveitis. Br J Ophtalmol 2003;87:423-31.
18. Bodaghi B, Gendron G, Wechsler B et al. Efficacy of interferon alpha in the treatment of refractory and sight threatening uveitis: A retrospective monocentric study of 45 patients. Br J Ophthalmol. 2007;91:335-9.
19. International study group for Behçet's disease. Criteria for the diagnosis of Behçet's disease. Lancet 1990;335:1078-80.
20. Kone-Paut I, Geisler I, Wechsler B et al. Familial aggregation in Behçet's disease: High frequency in siblings and parents of pediatric probands. J Pediatr 1999;135:89-93.
21. Molinari N, Kone-Paut I, Manna R et al. Identification of an autosomal recessive mode of inheritance in paediatric Behcet's families by segregation analysis. Am J Med Genet A 2003;122:115-8.
22. Calguneri M, Kiraz S, Ertenli I, Benekli M, Karaarslan Y, Celik I. The effect of prophylactic penicillin treatment on the course of arthritis episodes in patients with Behcet's disease. A randomized clinical trial. Arthritis Rheum 1996;39:2062-5.
23. Mason RM, Barnes CG. Behcet's syndrome with arthritis. Ann Rheum Dis 1969;28:95-103.
24. Hamuryudan V, Ozyazgan Y, Fresko Y, Mat C, Yurdakul S, Yazici H. Interferon alfa combined with azathioprine for the uveitis of Behcet's disease: An open study. Isr Med Assoc J 2002;4(Suppl. 11):928-30.
25. Guyer DR, Tiedeman J, Yannuzzi LA et al. Interferon-associated retinopathy. Arch Ophtalmol 1993;111:350-6.
26. Purvin VA. Anterior ischemic optic neuropathy secondary to interferon alfa. Arch Ophthalmol 1995;113:1041-4.
27. Wechsler B, Sable-Fourtassou R, Bodaghi B et al. Infliximab in refractory uveitis due to Behcet's disease. Clin Exp Rheumatol 2004;22(4 Suppl 34):S14-6.
28. Melikoglu M, Fresko I, Mat C et al. Short-term trial of etanercept in Behçet's disease: A double blinded, placebo controlled study. J Rheumatol 2005;32:98-105.